14Jul
Japan Tightens Foreign Direct Investment Regulations on Life Science Companies - Prior notification requirements under the Japanese regulations were expanded to cover investments in life science companies.
On June 15, 2020, the Japanese government implemented new regulations that designate the manufacture of pharmaceuticals for infectious diseases and the manufacture of highly-controlled medical devices (medical devices that are classified as Class III or Class IV in Japan, such as a heart–lung machines and ventilators) as both "Designated Businesses" and "Core Businesses" under the Foreign Exchange and Foreign Trade Act of Japan ("FEFTA"). The new regulations were adopted in light of the COVID-19...
By:
Jones Day
Related
Background - On June 12, 2019, the Dubai International Financial Center (“DIFC”) in Dubai, UAE a...
Read More >
On July 11, 2019, the Italian Government adopted Law Decree No. 64/2019 (DL 64/2019) which amends th...
Read More >
M&A in the US oil and gas sector faced significant headwinds in 2019, even before the COVID-19 pande...
Read More >
The US Supreme Court declined to review a recent Ninth Circuit decision, blocking the interim rules ...
Read More >
For employees boisterously raising employment-related concerns on behalf of a larger group, when mig...
Read More >
According to Refinitiv, a financial market data provider, the overall value of mergers and acquisiti...
Read More >